Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma

被引:50
作者
Ritter, M
Ali, MY
Grimm, CF
Weth, R
Mohr, L
Bocher, WO
Endrulat, K
Wedemeyer, H
Blum, HE
Geissler, M
机构
[1] Univ Hosp Freiburg, Dept Med 2, D-79106 Freiburg, Germany
[2] Univ Hosp Mainz, Dept Med, Mainz, Germany
[3] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
关键词
alpha-fetoprotein; cytotoxic T lymphocytes; dendritic cells; hepatocellular carcinoma; liver;
D O I
10.1016/j.jhep.2004.08.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Novel immunotherapeutic and other strategies are being explored for the treatment of hepatocellular carcinoma (HCC). Alpha-fetoprotein (AFP) may be a target antigen for immunotherapy. Little is known, however, about the immunobiology of AFP. Therefore, the impact of AFP on dendritic cells (DC), CD4 + and CD8 + T cells was studied in detail. Methods: Immune cells from peripheral blood of 27 HCC patients were studied using FACS, ELISPOT, and proliferation assays. Results: The in vitro generation, maturation, and T cell stimulatory capacity of DCs were not altered by AFP up to concentrations of 20 mug/ml. Higher AFP concentrations (> 20 mug/ml) resulted in phenotypic changes on DCs without impairing their capacity to stimulate CD4 + T cells. Frequencies and function of DCs and AFP specific T cells were not reduced in HCC patients independent on serum AFP levels. Finally, T lymphocytic infiltrations in the liver were not dependent on AFP serum levels. Conclusions: These studies clearly demonstrate that (i) DC-based immunotherapeutic approaches are a promising approach for HCC treatment and (ii) AFP-reactive T cell clones have not been deleted from the human T cell repertoire establishing AFP as a potential target for T cell based immunotherapy of HCC. (C) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:999 / 1007
页数:9
相关论文
共 42 条
[1]   ALPHA-FETOPROTEIN SUPPRESSES EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS [J].
ABRAMSKY, O ;
BRENNER, T ;
MIZRACHI, R ;
SOFFER, D .
JOURNAL OF NEUROIMMUNOLOGY, 1982, 2 (01) :1-7
[2]   Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma [J].
Allgaier, HP ;
Deibert, P ;
Zuber, I ;
Olschewski, M ;
Blum, HE .
LANCET, 1999, 353 (9165) :1676-1677
[3]   Radiofrequency thermal ablation of hepatocellular carcinoma [J].
Allgaier, HP ;
Galandi, D ;
Zuber, I ;
Blum, HE .
DIGESTIVE DISEASES, 2001, 19 (04) :301-310
[4]   SUPPRESSION OF PRIMARY CELL-MEDIATED IMMUNE-RESPONSE BY HUMAN ALPHA 1-FETOPROTEIN INVITRO [J].
AUER, IO ;
KRESS, HG .
CELLULAR IMMUNOLOGY, 1977, 30 (01) :173-179
[5]   Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection [J].
Bain, C ;
Fatmi, A ;
Zoulim, F ;
Zarski, JP ;
Trépo, C ;
Inchauspé, G .
GASTROENTEROLOGY, 2001, 120 (02) :512-524
[6]   Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type I response in vitro:: mechanisms for viral immune escape [J].
Beckebaum, S ;
Cicinnati, VR ;
Zhang, X ;
Ferencik, S ;
Frilling, A ;
Grosse-Wilde, H ;
Broelsch, CE ;
Gerken, G .
IMMUNOLOGY, 2003, 109 (04) :487-495
[7]   Epidemiology of primary liver cancer [J].
Bosch, FX ;
Ribes, J ;
Borràs, J .
SEMINARS IN LIVER DISEASE, 1999, 19 (03) :271-285
[8]  
BRENNER T, 1984, TUMOUR BIOL, V5, P263
[9]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[10]   Immunotherapy of hepatocellular carcinoma [J].
Butterfield, LH ;
Ribas, A .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (02) :123-133